ARYx shuts up shop as it waits out SPA response from FDA
This article was originally published in Scrip
Executive Summary
ARYx Therapeutics has failed to secure critical financing to enable it to continue operations and has shut up shop, blaming the US FDA for its delay in responding to ARYx' September SPA submission for naronapride. "Due to this delay and the lack of clarity as to the path forward for the development of naronapride, ARYx could not obtain the financing it expected to close in November", said the US firm.